BMJ Open publishes all reviews undertaken for accepted manuscripts. Reviewers are asked to complete a checklist review form (see an example) and are provided with free text boxes to elaborate on their assessment. These free text comments are reproduced below.
GENERAL COMMENTS
The study summarizes the latest literature on the comparative effectiveness of linezolid versus vancomycin in the treatment of hospital acquired pneumonia. There has been a continuous debate on whether linezolid offers a clinical advantage over vancomycin in achieving microbiologic eradication and clinical cure. The study is well written and confirms previous meta-analyses of the equivalency of both drugs in the management of HAP.
Comments: 1) The use of "definitive" systematic review is too strong as the selected studies are not similar in inclusion/exclusion criteria, diagnostic criteria, and concomitant therapy. The significance of the power of the study relates to the unique design of the study rather than a group of studies with different parameters. Suggest to change the terminology 2) it will be interesting to exclude the Proteus phenomenon as the first study was conducted more than a decade ago
3) It will be worthwhile to examine in a subgroup analysis studies using similar diagnostic criteria with vancomycin or linezolid remains controversial and is frequently debated on hospital rounds. There are multiple industry-sponsored trials suggesting that linezolid is associated with superior clinical outcomes; however, many of these studies have been criticized for methodological reasons. And while prior meta-analyses have concluded that the two therapies have similar efficacy risk a more recent clinical trial concluded that clinical outcomes were superior when hospital acquired MRSA pneumonia was treated with linezolid. The need for clarity regarding this controversy is plainly evident. If vancomycin is wrongly identified as being equivalent to linezolid in terms of efficacy than patients are at risk for worse clinical outcomes. On the other hand, if linezolid is wrongly perceived as being superior to vancomycin than patients are being exposed to a different set of potential adverse drug reactions and potentially higher health care costs.
Study Summary:
Nine randomized trial with a total of 4,026 patients were included. For the treatment of nosocomial pneumonia there were no differences detected between patients treated with linezolid or vancomycin in terms of clinical cure, microbiologic irradication or mortality. In terms of safety the two medications were similar in terms of nephrotoxicity, thrombocytopenia and rate of drug discontinuation due to adverse events
Overall Impression:
The question of whether to treat gram-positive nosocomial pneumonia with vancomycin or linezolid is remains extremelty relevant and timely. In general my review of this study is very favorable and I believe the results of this study-for the very reason that it is a "negative" study-need to discussed and summarized in high profile journal. I believe this study is the most complete and most compelling analysis on the subject that has been written to date. Criticisms and recommendation by section are as follows:
Title: Would either delete the word "Definitive" or replace with "updated." How does a "definitive" meta-analysis differ from a nondefinitive "meta-analysis?" Has a presumptive tone.
Abstract: no criticisms.
Introduction: Once again, I would avoid the use of "definitive." However, it is reasonable to mention that there is 100% statistical power to detect a mortality difference and that Pfizer is not planning to perform additional studies.
Materials and Methods: A discussion regarding how the decision was made to use absolute risk and not relative risk analysis would be worth mentioning either in this section or the Discussion section. Does changing to relative risk change the outcome significantly?
Results/Discussion: Once you abbreviate risk difference (RD) there is no longer the need to continue to repeat, "risk difference (RD)." Instead one can simply use "RD." Consider inclusion of a funnel plot to show presence/absence of publication bias. Combining nausea, vomiting, hepatitis and pancreatitis into one endpoint ("gastrointestinal events") is problematic. Nausea is clearly not the same as hepatitis and combining these two adverse events results in an endpoint that is nearly impossible to interpret. I would simply consider eliminating this figure or at least state the shortcoming associated with this combined endpoint. Is it possible to analyze the studies by comparing industry-sponsored versus not industry sponsored (I suspect most if not all are industry sponsored which might preclude this analysis)? Finally, it should be acknowledged that there are few (if any studies in the literature) in which one antibiotic has shown a mortality benefit when compared head-to-head with another antibiotic.
Figures:
Consider changing the scale on figure 2 to range from -.025 to 0.25. As the current figure is constructed it is unnecessarily small and the range from -.025 to -0.5 and 0.25 to 0.50 is "wasted" space. Also the figures should-whenever possible-have "favors linezolid" or "favors vancomycin" on the same side for each forest plot. Similarly, consider listing all the studies in each forest plot by year. Finally, all the trials are randomized and so it is not necessary to repeat this for each study. Not certain what the significance of the legend for each forest plot stating, "group by." Would simply change this to "randomized study design." Regarding figure 3a and 3b consider changing the titles to "clinical response among per intention to treat population" and "clinical response among per protocol population" respectively.
VERSION 1 -AUTHOR RESPONSE
Reviewer Comments:
Reviewer: 1
Recommendation:
Comments:
1) The use of "definitive" systematic review is too strong as the selected studies are not similar in inclusion/exclusion criteria, diagnostic criteria, and concomitant therapy. The significance of the power of the study relates to the unique design of the study rather than a group of studies with different parameters. Suggest to change the terminology AUTHORS' RESPONSE: Agreed. Manuscript title was changed accordingly.
2) it will be interesting to exclude the Proteus phenomenon as the first study was conducted more than a decade ago AUTHORS' RESPONSE: Agreed. However, the systematic review methodology does not allow for exclusion based on dates, particularly considering that this paper met the prospective inclusion criteria of our study. We followed the reviewer's suggestions and performed a sensitivity analysis without this study, which showed a RD = 0.001 (95% CI -0.018, 0.022); p=0.843. This finding was added to the results section.
3) It will be worthwhile to examine in a subgroup analysis studies using similar diagnostic criteria AUTHORS' RESPONSE: Thanks for the very good suggestion, but the diagnostic criteria reported in these trials did not allow for a subgroup analysis.
Reviewer: 2
Comments: Review of: Treatment of Hospital-Acquired Pneumonia with Linezolid or Vancomycin: A definitive Meta-Analysis
Background:
Whether to treat hospital-acquired gram positive pneumonia-in particular, methicillin-resistant Staphylococcus aureus pneumonia--with vancomycin or linezolid remains controversial and is frequently debated on hospital rounds. There are multiple industry-sponsored trials suggesting that linezolid is associated with superior clinical outcomes; however, many of these studies have been criticized for methodological reasons. And while prior meta-analyses have concluded that the two therapies have similar efficacy risk a more recent clinical trial concluded that clinical outcomes were superior when hospital acquired MRSA pneumonia was treated with linezolid. The need for clarity regarding this controversy is plainly evident. If vancomycin is wrongly identified as being equivalent to linezolid in terms of efficacy than patients are at risk for worse clinical outcomes. On the other hand, if linezolid is wrongly perceived as being superior to vancomycin than patients are being exposed to a different set of potential adverse drug reactions and potentially higher health care costs.
Study Summary:
Nine randomized trial with a total of 4,026 patients were included. For the treatment of nosocomial pneumonia there were no differences detected between patients treated with linezolid or vancomycin in terms of clinical cure, microbiologic eradication or mortality. In terms of safety the two medications were similar in terms of nephrotoxicity, thrombocytopenia and rate of drug discontinuation due to adverse events
The question of whether to treat gram-positive nosocomial pneumonia with vancomycin or linezolid is remains extremely relevant and timely. In general my review of this study is very favorable and I believe the results of this study-for the very reason that it is a "negative" study-need to discussed and summarized in high profile journal. I believe this study is the most complete and most compelling analysis on the subject that has been written to date. Criticisms and recommendation by section are as follows:
Title: Would either delete the word "Definitive" or replace with "updated." How does a "definitive" meta-analysis differ from a nondefinitive "meta-analysis?" Has a presumptive tone. AUTHORS' RESPONSE: Agreed. Manuscript title was changed accordingly.
Abstract: no criticisms. AUTHORS' RESPONSE: Thanks.
Introduction: Once again, I would avoid the use of "definitive." However, it is reasonable to mention that there is 100% statistical power to detect a mortality difference and that Pfizer is not planning to perform additional studies. AUTHORS' RESPONSE: Agreed and removed accordingly.
Materials and Methods: A discussion regarding how the decision was made to use absolute risk and not relative risk analysis would be worth mentioning either in this section or the Discussion section. Does changing to relative risk change the outcome significantly? AUTHORS' RESPONSE: Agreed. We performed all analyses with both measures and the results remained similar across both overall and subgroup analyses. We added a sentence to the methods' section regarding the choice of the measure estimate.
Results/Discussion: Once you abbreviate risk difference (RD) there is no longer the need to continue to repeat, "risk difference (RD)." Instead one can simply use "RD." Consider inclusion of a funnel plot to show presence/absence of publication bias. Combining nausea, vomiting, hepatitis and pancreatitis into one endpoint ("gastrointestinal events") is problematic. Nausea is clearly not the same as hepatitis and combining these two adverse events results in an endpoint that is nearly impossible to interpret. I would simply consider eliminating this figure or at least state the shortcoming associated with this combined endpoint. Is it possible to analyze the studies by comparing industry-sponsored versus not industry sponsored (I suspect most if not all are industry sponsored which might preclude this analysis)? Finally, it should be acknowledged that there are few (if any studies in the literature) in which one antibiotic has shown a mortality benefit when compared head-to-head with another antibiotic. AUTHORS' RESPONSE: Agreed. We removed the "risk difference" repeats. We preferred to keep the overall GI events figure due to the importance of safety and side-effects, but we followed the reviewer's suggestion and stated its shortcomings in the limitation paragraph of the discussion section. We could not perform an analysis based on industry sponsoring since all trials were sponsored by industry. Agree with the acknowledgment of mortality benefit issues and added to the manuscript's discussion as well.
Figures:
Consider changing the scale on figure 2 to range from -.025 to 0.25. As the current figure is constructed it is unnecessarily small and the range from -.025 to -0.5 and 0.25 to 0.50 is "wasted" space. Also the figures should-whenever possible-have "favors linezolid" or "favors vancomycin" on the same side for each forest plot. Similarly, consider listing all the studies in each forest plot by year. Finally, all the trials are randomized and so it is not necessary to repeat this for each study. Not certain what the significance of the legend for each forest plot stating, "group by." Would simply change this to "randomized study design." Regarding figure 3a and 3b consider changing the titles to
